Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BYS10 in RET-altered advanced solid tumors
ChiCTR2400085264Phase 2Recruiting
- Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of BYS10 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), thyroid cancer and 1 more (2 arms), sponsored by Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Dose-limiting toxicity incidence and category, Adverse events and 3 more. Started Jun 2024; status: recruiting.
02
Drugs
BYS10
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)thyroid cancerMedullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on ChiCTR2400085264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085264.